Startups
2019
CarboCalyxCarboCalyx GmbH is a glycopharmaceutical startup company dedicated for the establishment of novel immunomodulatory biologics using cellular modifications, glycoengineering and targeted immunotherapy. Our technologies are suitable for clinical testing in various disease conditions. We aim to develop personalized vaccination methodologies for patients fighting against cancer and to generate a repertoire of innovative opportunities to control infectious diseases.
Address
Byk-Gulden-Straße 2, 78467 Konstanz, Germany
Commercial Register
Registered with the Amtsgericht Freiburg
HRB 720764
Details
Customer Problem
Challenges to overcome in cancer immunotherapy:
• Tumor cells are unique (clonal heterogeneity, branching evolution; immunoevasion)
• Personalized approaches (focus on neoantigens, sequencing and translational editing; hurdles of instability and in vivo delivery)
Promising state-of-the-art for glycoengineering in cell therapy:
• Single carbohydrate-based approaches have reached deep into clinical trials
• Bottleneck: straight up bet on a single molecule. We are all individual. So is our antibody repertoire.Technology Description
Maximizing immunogenicity through autologous whole-
cell therapy:
❖ overcomes heterogeneity, evolution andimmunoevasion
❖ high biocompatibility
• Introduction of an innovative chemical technology platform:
❖ harnesses the patient’s own anti-carbohydrate antibody repertoire
❖ allows for an immunogenic carbohydrate library to a yet unprecedented scale (→ personalized selection of targets)
❖ no need for genetic manipulation (quick and simple protocol conditions)
❖ scalable production and no in vivo byproducts (suitable for GMP production, safe and stable applicability in vivo)Finance Data
| Date | Investors | Amount | Stage |
Financial Overview
No revenue recorded yet
Seed
Individual Attributes
Funding Status
Lakeside Dealflow & Lifecycle Status